PureTech Health: Results of Annual General Meeting
PRTCBOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting
June 16, 2025AGM
Read more →PureTech Health: Results of Annual General Meeting
PRTCBOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting
June 16, 2025AGM
Read more →PureTech Presents Phase 2b Data For Deupirfenidone At ATS 2025, Showing Statistically Significant Slowing Of IPF Progression With Durable Effect Over 52 Weeks, Favorable Safety Profile, And Plans For FDA Meeting And Phase 3 Trial Launch By End Of 2025
PRTCMay 20, 2025
Read more →PureTech Announces Publication Of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis
PRTCMay 9, 2025
Read more →PureTech Says It Will Present Results From Phase 2b ELEVATE IPF Trial Of Deupirfenidone (LYT-100) At American Thoracic Society International Conference, Regulatory And Strategic Planning Underway To Advance Deupirfenidone Into Phase 3 Development
PRTCMay 1, 2025
Read more →PureTech Health FY EPS $0.21 Up From $(0.24) YoY, Sales $4.83M Up From $3.33M YoY
PRTCApril 30, 2025
Read more →PureTech Health Confirms Ongoing Discussions With Nordic Capital Regarding Possible Cash Offer For Entire Share Capital, With A Decision Expected By May 5, 2025
PRTCApril 7, 2025
Read more →PureTech Founded Entity Seaport Therapeutics Announces Publication Of Research Demonstrating Increased Lymphatic Transport With Up To 55% Drug Absorption Via Lymphatics With GlyphTM Platform
PRTCFebruary 12, 2025
Read more →The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia
PRTCJanuary 9, 2025
Read more →PureTech Health Announces Launch of $100M Tender Offer At Premium Price of 250 Pence Per Share
PRTCMay 20, 2024
Read more →